Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
131.4 ^USD	-1.02%		-0.33%	+36.24%

05-17	Mizuho Adjusts Price Target on Sarepta Therapeutics to $179 From $145, Maintains Buy Rating	MT
05-14	Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180	MT

Sarepta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 01, 2024 at 04:02 pm

Sarepta Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 413.46 million compared to USD 253.5 million a year ago. Net income was USD 36.12 million compared to net loss of USD 516.76 million a year ago.

Basic earnings per share from continuing operations was USD 0.38 compared to basic loss per share from continuing operations of USD 5.86 a year ago. Diluted earnings per share from continuing operations was USD 0.37 compared to diluted loss per share from continuing operations of USD 5.86 a year ago.

Latest news about Sarepta Therapeutics, Inc.

Mizuho Adjusts Price Target on Sarepta Therapeutics to $179 From $145, Maintains Buy Rating	05-17	MT
Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180	05-14	MT
Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says	05-02	MT
UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating	05-02	MT
Morgan Stanley Raises Price Target on Sarepta Therapeutics to $165 From $160, Keeps Overweight Rating	05-02	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 EPS $0.73, vs. Street Est of $0.30	05-01	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Revenue $413.5M, vs. Street Est of $370.5M	05-01	MT
Sarepta Therapeutics Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Rise After Hours	05-01	MT
Transcript : Sarepta Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024	05-01
Sarepta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
FDA greenlights Italfarmaco's drug for rare muscular dystrophy	03-21	RE
Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM	03-12
Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing	03-12	MT
Transcript : Sarepta Therapeutics, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 10:00 AM	03-11
Sarepta Therapeutics Insider Sold Shares Worth $385,480, According to a Recent SEC Filing	03-07	MT
UBS Raises Sarepta Therapeutics Price Target to $167 From $164, Maintains Buy Rating	03-01	MT
Sarepta Therapeutics' Regulatory Drug Review Underpins Prospects for Rally, RBC Says	02-29	MT
Deutsche Bank Cuts Sarepta Therapeutics Price Target to $156 From $158, Maintains Buy Rating	02-29	MT
Needham Cuts Price Target on Sarepta Therapeutics to $166 From $169, Maintains Buy Rating	02-29	MT
RBC Boosts Price Target on Sarepta Therapeutics to $157 From $151, Keeps Outperform Rating	02-29	MT
Sarepta Therapeutics Swings to Q4 Profit, Revenue Increases; Shares Rise After Market	02-28	MT
Transcript : Sarepta Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	02-28
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 Revenue $396.8M, vs. Street Est of $386.2M	02-28	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 EPS $0.82, vs. Street Est of $0.37	02-28	MT
Sarepta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI

Chart Sarepta Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Sector

Biotechnology & Medical Research

Calendar

2024-06-06 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Sarepta Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

131.4 USD

Average target price

168.2 USD

Spread / Average Target

+28.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.84B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
LEGEND BIOTECH CORPORATION	-24.95%	8.23B

Bio Therapeutic Drugs